{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:11:10Z","timestamp":1791655870126,"version":"4.3.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,5,16]],"date-time":"2015-05-16T00:00:00Z","timestamp":1431734400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007110","name":"Schering-Plo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007110","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merch Sharp et Dohme"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s10549-015-3415-2","type":"journal-article","created":{"date-parts":[[2015,5,15]],"date-time":"2015-05-15T04:39:59Z","timestamp":1431664799000},"page":"597-606","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study"],"prefix":"10.1007","volume":"151","author":[{"given":"Miguel J.","family":"Gil-Gil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bellet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Ojeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Manso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mesia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Garcia-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Martinez-J\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mel\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Llombart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pernas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Villagrasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Blasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Baselga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,16]]},"reference":[{"key":"3415_CR1","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists\u2019s Group","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019s Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687\u20131717","journal-title":"Lancet"},{"key":"3415_CR2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1200\/JCO.2001.19.1.37","volume":"19","author":"M Zambetti","year":"2001","unstructured":"Zambetti M, Moliterni A, Materazzo C et al (2001) Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol 19:37\u201343","journal-title":"J Clin Oncol"},{"key":"3415_CR3","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1200\/JCO.2004.03.516","volume":"22","author":"EA Perez","year":"2004","unstructured":"Perez EA, Suman VJ, Davidson NE et al (2004) Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol 22:3700\u20133704","journal-title":"J Clin Oncol"},{"key":"3415_CR4","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","volume":"91","author":"DD Hoff Von","year":"1979","unstructured":"Von Hoff DD, Layard MW, Basa P et al (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710\u2013717","journal-title":"Ann Intern Med"},{"key":"3415_CR5","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","volume":"25","author":"MC Pinder","year":"2007","unstructured":"Pinder MC, Duan Z, Goodwin JS et al (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25:3808\u20133815","journal-title":"J Clin Oncol"},{"key":"3415_CR6","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1200\/JCO.2005.02.5841","volume":"23","author":"JJ Doyle","year":"2005","unstructured":"Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL (2005) Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol 23:8597\u20138605","journal-title":"J Clin Oncol"},{"key":"3415_CR7","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1002\/cncr.24621","volume":"115","author":"XL Du","year":"2009","unstructured":"Du XL, Xia R, Liu CC et al (2009) Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer. Cancer 115:5296\u20135308","journal-title":"Cancer"},{"key":"3415_CR8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1023\/A:1008216430806","volume":"9","author":"G Berry","year":"1998","unstructured":"Berry G, Billingham M, Alderman E et al (1998) The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi\u2019s sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 9:711\u2013716","journal-title":"Ann Oncol"},{"key":"3415_CR9","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1023\/A:1008365716693","volume":"11","author":"T Safra","year":"2000","unstructured":"Safra T, Muggia F, Jeffers S et al (2000) Pegylated liposomal doxorubicin (Doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500\u00a0mg\/m2. Ann Oncol 11:1209\u20131233","journal-title":"Ann Oncol"},{"key":"3415_CR10","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","volume":"15","author":"ME O\u2019Brien","year":"2004","unstructured":"O\u2019Brien ME, Wigler N, Inbar M et al (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15:440\u2013449","journal-title":"Ann Oncol"},{"key":"3415_CR11","first-page":"987","volume":"54","author":"A Gabizon","year":"1994","unstructured":"Gabizon A, Catane R, Uziely B et al (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54:987\u2013992","journal-title":"Cancer Res"},{"key":"3415_CR12","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z","volume":"89","author":"O Lyass","year":"2000","unstructured":"Lyass O, Uziely B, Ben-Yosef R et al (2000) Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (doxil) in metastatic breast carcinoma. Cancer 89:1037\u20131047","journal-title":"Cancer"},{"key":"3415_CR13","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/cncr.10741","volume":"95","author":"B Fisher","year":"2002","unstructured":"Fisher B, Bryant J, Wolmark N et al (2002) Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 95:681\u2013695","journal-title":"Cancer"},{"key":"3415_CR14","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1200\/JCO.20.6.1456","volume":"20","author":"IC Smith","year":"2002","unstructured":"Smith IC, Heys SD, Hutcheon AW et al (2002) Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20:1456\u20131466","journal-title":"J Clin Oncol"},{"key":"3415_CR15","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1200\/JCO.2005.05.078","volume":"23","author":"G Minckwitz von","year":"2005","unstructured":"von Minckwitz G, Raab G, Caputo A et al (2005) Doxorubicin with cyclophosphamide followed by docetaxel every 21\u00a0days compared with doxorubicin and docetaxel every 14\u00a0days as preoperative treatment in operable breast cancer: the GEPARDUE Study of the German Breast Group. J Clin Oncol 23:2676\u20132685","journal-title":"J Clin Oncol"},{"key":"3415_CR16","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.1999.17.11.3412","volume":"17","author":"AU Buzdar","year":"1999","unstructured":"Buzdar AU, Singletary SE, Theriault RL et al (1999) Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 17:3412\u20133417","journal-title":"J Clin Oncol"},{"key":"3415_CR17","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1200\/JCO.2003.01.136","volume":"21","author":"M Kaufmann","year":"2003","unstructured":"Kaufmann M, von Minckwitz G, Smith R et al (2003) International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 21:2600\u20132608","journal-title":"J Clin Oncol"},{"key":"3415_CR18","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1200\/JCO.2004.02.122","volume":"22","author":"V Dieras","year":"2004","unstructured":"Dieras V, Fumoleau P, Romieu G et al (2004) Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 22:4958\u20134965","journal-title":"J Clin Oncol"},{"key":"3415_CR19","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1200\/JCO.2005.06.156","volume":"23","author":"TR Evans","year":"2005","unstructured":"Evans TR, Yellowlees A, Foster E et al (2005) Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an Anglo-Celtic Cooperative Oncology Group study. J Clin Oncol 23:2988\u20132995","journal-title":"J Clin Oncol"},{"key":"3415_CR20","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1200\/JCO.2005.04.1665","volume":"24","author":"HD Bear","year":"2006","unstructured":"Bear HD, Anderson S, Smith RE et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019\u20132027","journal-title":"J Clin Oncol"},{"key":"3415_CR21","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cncr.23544","volume":"113","author":"F Cuppone","year":"2008","unstructured":"Cuppone F, Bria E, Carlini P et al (2008) Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials. Cancer 113:238\u2013246","journal-title":"Cancer"},{"key":"3415_CR22","unstructured":"Pathological complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval. http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm"},{"issue":"2","key":"3415_CR23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/annonc\/mdu551","volume":"26","author":"H Bonnefoi","year":"2015","unstructured":"Bonnefoi H, Jacot W, Saghatchian M et al (2015) Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline based chemotherapy in HER2-positive breast cancer: results of the randomized phase IIU EPRTC 10054 study. Ann Oncol 26(2):325\u2013332","journal-title":"Ann Oncol"},{"key":"3415_CR24","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/sj.bjc.6604868","volume":"100","author":"A Barnadas","year":"2009","unstructured":"Barnadas A, Gil M, Gonz\u00e1lez S et al (2009) Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial. Br J Cancer 100:442\u2013449","journal-title":"Br J Cancer"},{"key":"3415_CR25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3816\/CBC.2005.n.017","volume":"2","author":"B Overmoyer","year":"2005","unstructured":"Overmoyer B, Silverman P, Holder LW et al (2005) Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer. Clin Breast Cancer 2:150\u2013157","journal-title":"Clin Breast Cancer"},{"key":"3415_CR26","doi-asserted-by":"crossref","first-page":"5906","DOI":"10.1200\/JCO.2009.22.7504","volume":"27","author":"ME Trudeau","year":"2009","unstructured":"Trudeau ME, Clemons MJ, Provencher L et al (2009) Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines. J Clin Oncol 27:5906\u20135910","journal-title":"J Clin Oncol"},{"key":"3415_CR27","unstructured":"Srimuninnimit V, Sinlaratana P, Bhothisuwan K et al (2002) Phase II study with the combination of pegylated liposomal doxorubicin (Caelyx) and cyclophosphamide (CC) in locally advanced breast cancer (LABC). J Clin Oncol 21(abstr 279)"},{"key":"3415_CR28","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1093\/annonc\/mdf284","volume":"13","author":"H Gogas","year":"2002","unstructured":"Gogas H, Papadimitriou C, Kalofonos HP et al (2002) Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx\u00ae) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group. Ann Oncol 13:1737\u20131742","journal-title":"Ann Oncol"},{"key":"3415_CR29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.breast.2004.01.006","volume":"13","author":"DA Vorobiof","year":"2004","unstructured":"Vorobiof DA, Rapoport BL, Chasen MR et al (2004) First line therapy with paclitaxel (Taxol) and Pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer: a multicentre phase II study. Breast 13:219\u2013226","journal-title":"Breast"},{"key":"3415_CR30","first-page":"1817","volume":"10","author":"S Rigatos","year":"2003","unstructured":"Rigatos S, Tsavraridis D, Athanasiadis A, Stathopoulos JG, Stathopoulos G (2003) Paclitaxel and liposomal doxorubicin (Caelyx) combination in advanced breast cancer patient: a phase II study. Oncol Rep 10:1817\u20131819","journal-title":"Oncol Rep"},{"key":"3415_CR31","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Mata J, Calvo L, L\u00f3pez R et al (2011) Non-randomized, open label phase II trial evaluating the safety and efficacy of taxotere (T) followed by myocet (M)\u00a0+\u00a0cyclophosphamide (C) as first-line treatment for HER2-negative breast cancer (BC). Cancer Res 71(Suppl 3)","DOI":"10.1158\/0008-5472.SABCS11-P3-14-15"},{"key":"3415_CR32","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1056\/NEJM199912303412706","volume":"341","author":"LF Hutchins","year":"1999","unstructured":"Hutchins LF, Unger JM, Crowley JJ et al (1999) Underrepresentation of patients 65\u00a0years of age or older in cancer-treatment trials. N Engl J Med 341:2061\u20132067","journal-title":"N Engl J Med"},{"key":"3415_CR33","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1093\/annonc\/mdr024","volume":"22","author":"M Martin","year":"2011","unstructured":"Martin M, S\u00e1nchez-Rovira P, Mu\u00f1oz M et al (2011) Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM\/2004\u201305 study. Ann Oncol 22:2591\u20132596","journal-title":"Ann Oncol"},{"key":"3415_CR34","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1200\/JCO.2005.03.8331","volume":"24","author":"S Chia","year":"2006","unstructured":"Chia S, Clemons M, Martin LA et al (2006) Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol 24:2773\u20132778","journal-title":"J Clin Oncol"},{"key":"3415_CR35","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.ejca.2005.12.011","volume":"42","author":"RE Coleman","year":"2006","unstructured":"Coleman RE, Biganzoli L, Canney P et al (2006) A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur J Cancer 42:882\u2013887","journal-title":"Eur J Cancer"},{"key":"3415_CR36","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000093005","volume":"70","author":"SE Al-Batran","year":"2006","unstructured":"Al-Batran SE, Meerpohl HG, von Minckwitz G et al (2006) Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40\u00a0mg\/m2 every 4\u00a0weeks in previously treated patients with metastatic breast cancer. Oncology 70:141\u2013146","journal-title":"Oncology"},{"key":"3415_CR37","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","volume":"25","author":"DG Mutch","year":"2007","unstructured":"Mutch DG, Orlando M, Goss T et al (2007) Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25:2811\u20132818","journal-title":"J Clin Oncol"},{"key":"3415_CR38","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2009.11.026","volume":"16","author":"M Markman","year":"2010","unstructured":"Markman M, Moon J, Wilczynski S et al (2010) Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecol Oncol 16:323\u2013325","journal-title":"Gynecol Oncol"},{"key":"3415_CR39","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","volume":"28","author":"E Pujade-Lauraine","year":"2010","unstructured":"Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al (2010) Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28:3323\u20133329","journal-title":"J Clin Oncol"},{"key":"3415_CR40","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2003.03.111","volume":"21","author":"E Rivera","year":"2003","unstructured":"Rivera E, Valero V, Arun B et al (2003) Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol 21:3249\u20133254","journal-title":"J Clin Oncol"},{"key":"3415_CR41","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1200\/JCO.2007.10.9710","volume":"25","author":"HB Muss","year":"2007","unstructured":"Muss HB, Berry DA, Cirrincione C et al (2007) Toxicity of older and young patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol 25:3699\u20133704","journal-title":"J Clin Oncol"},{"key":"3415_CR42","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JOP.2014.001388","volume":"10","author":"HD Klepin","year":"2014","unstructured":"Klepin HD, Pitcher BN, Ballman KV et al (2014) Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on clinical trial: CALGB 49907 and CALGB 361004 (Alliance). J Oncol Pract 10:285\u2013292","journal-title":"J Oncol Pract"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-015-3415-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-015-3415-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-015-3415-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,25]],"date-time":"2019-08-25T00:15:47Z","timestamp":1566692147000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-015-3415-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,16]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["3415"],"URL":"https:\/\/doi.org\/10.1007\/s10549-015-3415-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,16]]}}}